Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total value of $159,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, August 8th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $30.57, for a total value of $152,850.00.
  • On Tuesday, July 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $32.53, for a total value of $162,650.00.

Shares of Genomic Health, Inc. (GHDX) opened at 31.27 on Friday. The company’s market cap is $1.08 billion. The company’s 50-day moving average price is $30.90 and its 200 day moving average price is $31.60. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative net margin of 1.50% and a negative return on equity of 4.33%. The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same period in the previous year, the business posted ($0.18) EPS. Genomic Health’s revenue was up 4.3% compared to the same quarter last year. Equities analysts predict that Genomic Health, Inc. will post ($0.01) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/16/g-bradley-cole-sells-5000-shares-of-genomic-health-inc-ghdx-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Genomic Health by 6.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock valued at $54,379,000 after acquiring an additional 106,452 shares in the last quarter. Columbia Wanger Asset Management LLC lifted its position in Genomic Health by 26.1% in the 1st quarter. Columbia Wanger Asset Management LLC now owns 1,607,649 shares of the medical research company’s stock valued at $50,625,000 after acquiring an additional 332,311 shares in the last quarter. Renaissance Technologies LLC lifted its position in Genomic Health by 10.9% in the 2nd quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock valued at $26,473,000 after acquiring an additional 80,100 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in Genomic Health by 10.0% in the 1st quarter. Loomis Sayles & Co. L P now owns 584,515 shares of the medical research company’s stock valued at $18,406,000 after acquiring an additional 53,344 shares in the last quarter. Finally, State Street Corp lifted its position in Genomic Health by 2.5% in the 2nd quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock valued at $16,840,000 after acquiring an additional 12,696 shares in the last quarter. 88.91% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently issued reports on GHDX shares. Jefferies Group LLC reiterated a “hold” rating and set a $33.00 target price on shares of Genomic Health in a report on Monday, June 12th. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Cowen and Company reiterated a “hold” rating and set a $34.00 target price on shares of Genomic Health in a report on Friday, September 1st. Canaccord Genuity dropped their target price on Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. Finally, BidaskClub lowered Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $32.00.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.